TScan Therapeutics (TCRX) Current Assets (2020 - 2026)
TScan Therapeutics (TCRX) posted quarterly Current Assets of $132.8 million for Q1 2026, down 47.9% year-over-year from $254.8 million in Q1 2025, and down 15.55% quarter-over-quarter from $157.2 million in Q4 2025.
TScan Therapeutics (TCRX) Current Assets (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Current Assets for 7 consecutive years, with $132.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets fell 47.9% year-over-year to $132.8 million; the TTM figure through Mar 2026 stood at $132.8 million (down 47.9% YoY), while the FY2025 annual figure was $157.2 million, down 46.29% from the prior year.
- Current Assets retreated to $132.8 million in Q1 2026 per TCRX's latest filing, from $157.2 million in the prior quarter.
- Across five years, Current Assets topped out at $299.5 million in Q2 2024 and bottomed at $100.9 million in Q1 2023.
- Historically, Current Assets has averaged $193.0 million across 5 years, with a median of $188.2 million in 2025.
- Annual changes were most pronounced in 2023 — Current Assets surged 87.24% — and 2026, when it tumbled 47.9%.
- TScan Therapeutics' Current Assets stood at $124.1 million in 2022, then surged by 56.48% to $194.2 million in 2023, then soared by 50.7% to $292.7 million in 2024, then plunged by 46.29% to $157.2 million in 2025, then retreated by 15.55% to $132.8 million in 2026.
- Business Quant data shows TCRX's Current Assets at $132.8 million in Q1 2026, $157.2 million in Q4 2025, and $188.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - | 104.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 104.40 Mn |
| Mar 31, 2026 | 132.77 Mn |
| Dec 31, 2025 | 157.21 Mn |
| Sep 30, 2025 | 188.17 Mn |
| Jun 30, 2025 | 221.13 Mn |
| Mar 31, 2025 | 254.84 Mn |
| Dec 31, 2024 | 292.72 Mn |
| Sep 30, 2024 | 274.09 Mn |
| Jun 30, 2024 | 299.53 Mn |
| Mar 31, 2024 | 164.72 Mn |
| Dec 31, 2023 | 194.24 Mn |
| Sep 30, 2023 | 217.57 Mn |
| Jun 30, 2023 | 242.22 Mn |
| Mar 31, 2023 | 100.91 Mn |
| Dec 31, 2022 | 124.13 Mn |
| Sep 30, 2022 | 141.18 Mn |
| Jun 30, 2022 | 129.36 Mn |
| Mar 31, 2022 | 145.75 Mn |
| Dec 31, 2021 | 165.65 Mn |
| Sep 30, 2021 | 187.00 Mn |